In 2022, the market for chimeric antigen receptor (CAR) T-cell therapy will be worth $2.54 billion USD. The market is anticipated to reach US$ 3.5 billion in market value by 2023 and finally reach US$ 6.82 billion by exhibiting a CAGR of 6.9% from 2023 to 2033. The need for individualised medicines and technical improvements can be linked to the expansion of the chimeric antigen receptor (CAR) T-Cell therapy market. In the historical period from 2018 to 2022, the market for chimeric antigen receptor (CAR) T-cell therapy recorded a CAGR of 7%.
One of the key advantages of CAR T-cell therapy is its high efficacy rates. In clinical trials, CAR T-cell therapy has demonstrated response rates of up to 90% in certain types of leukemia and lymphoma. This is a significant improvement over traditional cancer therapies, which typically have response rates of around 20-30%.
Get a holistic overview of the market from industry experts to evaluate and develop growth strategies. Download the sample @
https://www.futuremarketinsights.com/reports/sample/rep-gb-16808
Another advantage of CAR T-cell therapy is its potential to provide long-lasting remissions. In some patients, CAR T-cell therapy has led to complete remission, meaning that there is no evidence of cancer in the body. This is a particularly promising result for patients with relapsed or refractory cancers, who have exhausted all other treatment options.
The CAR T-cell therapy market is expected to continue to grow in the coming years as more clinical trials are conducted and more therapies are approved. In addition to the two currently approved therapies, there are several other CAR T-cell therapies in late-stage clinical development for various types of cancers. The market is also expected to benefit from advancements in gene editing technology, which could enable the development of CAR T-cell therapies that are more effective and have fewer side effects.
Key Takeaways from the Market Study
- The Chimeric antigen receptor (CAR) T-Cell therapy market is expected to grow at a CAGR of 6.9% in the forecast period 2023 to 2033.
- By type, Yescarta is expected to hold 45% of the market share in 2023 for Chimeric antigen receptor (CAR) T-Cell therapy market.
- North America is expected to possess 45% market share for Chimeric antigen receptor (CAR) T-Cell therapy market in 2023.
- Europe Chimeric antigen receptor (CAR) T-Cell therapy market size is expected to possess 39% market share in 2023.
“The increasing incidence of cancer, rising demand for personalized medicine, and advancements in CAR T-cell therapy are some of the major factors driving the growth of the market,” states an FMI analyst.
For insights on global, regional, and country-level parameters with growth opportunities from 2023 to 2033, Ask An Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-16808
Competitive Landscape
Key players in the Chimeric antigen receptor (CAR) T-Cell therapy market are Abbott Laboratories, Baxter International Inc., Becton, Dickinson and Company, Boston Scientific Corporation, Fresenius SE & Co. KGaA, Johnson & Johnson, Medtronic PLC, Novartis AG, Endo International PLC and Pfizer Inc.
- BD has contributed to CAR T-cell therapy is through its flow cytometry technology, which is used to monitor the manufacturing and quality control of CAR T-cell therapies. Flow cytometry is a technique that allows researchers and clinicians to analyze and sort individual cells based on their physical and chemical characteristics. BD offers a range of flow cytometry instruments and reagents that are used to monitor the T-cells used in CAR T-cell therapy, as well as the cancer cells targeted by these therapies.
- Boston Scientific has contributed to CAR T-cell therapy through its interventional oncology products. These products are designed to treat cancer through minimally invasive procedures, such as tumor ablation or embolization. While these procedures are not directly related to CAR T-cell therapy, they can be used to manage complications that may arise during or after CAR T-cell treatment, such as bleeding or swelling in the liver.
More Valuable Insights
Future Market Insights, in its new offering, presents an unbiased analysis of the global chimeric antigen receptor (CAR) T-Cell therapy market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
The study reveals essential insights on the basis of Type (Abecma, Breyanzi, Kymriah, Tecartus, Yescarta, Others) Application (Leukemia, Lymphoma, Multiple Myeloma, Autoimmune Disorders, Other Application) End User Hospitals and Cancer Care Treatment Centers) Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
Last few days to get reports at discounted prices, offer expires soon!
Request Discount @ https://www.futuremarketinsights.com/request-discount/rep-gb-16808
Key Segments Profiled in the Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Survey
By Type:
- Abecma
- Breyanzi
- Kymriah
- Tecartus
- Yescarta
- Others
By Application:
- Leukemia
- Lymphoma
- Multiple Myeloma
- Autoimmune Disorders
- Other Application
By End User:
- Hospitals
- Cancer Care Treatment Centers
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
About Us
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs
